Difference between revisions of "Prostate cancer, BRCA-mutated"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable sortable" style="width: 75%; text-align:center;"" to "{| class="wikitable sortable" style="width: 60%; text-align:center;"") |
Warner-admin (talk | contribs) m (Text replacement - "|Phase II" to "|Phase 2") |
||
| Line 32: | Line 32: | ||
|(TRITON2) | |(TRITON2) | ||
|2017-NR | |2017-NR | ||
| − | |style="background-color:#91cf61"|Phase | + | |style="background-color:#91cf61"|Phase 2 (RT) |
|- | |- | ||
|} | |} | ||
Revision as of 17:45, 12 February 2022
| Page editor | Section editor | ||
|---|---|---|---|
 |
Laura S. Graham, MD University of Washington Fred Hutchinson Cancer Research Center Seattle, WA  LauraGrahamMD
|
 |
Ali Raza Khaki, MD Stanford University Palo Alto, CA arkhaki
|
7 regimens on this page
8 variants on this page
|
Note: this page has regimens which are specific to prostate cancer that is BRCA-mutated. Please see the main prostate cancer page for other regimens.
Metastatic castration-resistant
Rucaparib monotherapy
| back to top |
Regimen
| Study | Years of enrollment | Evidence |
|---|---|---|
| (TRITON2) | 2017-NR | Phase 2 (RT) |
Note: this study is the basis of FDA approval; however, no dosing details are provided on CT.gov and there are no published manuscripts to date.
Targeted therapy
References
- TRITON2: NCT02952534